Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-
care systems. Improving metabolic control to approach normal glycaemia (where practical) …

Moderate aLimited use in the US/Europe. bNot licensed in the US cPrescribing highly
restricted in the US; withdrawn in Europe. dNot licensed in Europe. eTo be available as a …

Glycaemic management in type 2 diabetes mellitus has become increasingly complex and,
to some extent, controversial, with a widening array of pharmacological agents now …

The management of T2DM requires aggressive treatment to achieve glycemic and
cardiovascular risk factor goals. In this setting, metformin, an old and widely accepted first …

Metformin is a biguanide that is used as first-line treatment of type 2 diabetes mellitus and is
effective as monotherapy and in combination with other glucose-lowering medications. It is …

OBJECTIVE—Lactic acidosis has been associated with use of metformin. Hypoglycemia is a
major concern using sulfonylureas. The aim of this study was to compare the risk of lactic …

Background: Metformin toxicity, a challenging clinical entity, is associated with a mortality of
30%. The role of extracorporeal treatments such as hemodialysis is poorly defined at …

Metformin is now established as a first-line antidiabetic therapy for the management of type
2 diabetes. Its early use in treatment algorithms is supported by lack of weight gain, low risk …

Lactic acidosis associated with metformin treatment is a rare but important adverse event,
and unravelling the problem is critical. First, this potential event still influences treatment …

Metformin is unanimously considered a first-line glucose-lowering agent. Theoretically,
however, it cannot be prescribed in a large proportion of patients with type 2 diabetes …